
Sen-Jam Pharmaceutical, a NYC-based company which specializes in solutions targeting inflammation and metabolic health, received an investment from 5 Horizons Capital.
The amount of the deal was not disclosed.
The company intends to use the funds to delivering scalable and accessible solutions that enhance global health outcomes.
Led by CEO Jim Iversen, Sen-Jam Pharmaceutical is a biotech company empowering the treatment landscape for inflammation and metabolic disorders through its proprietary “Pleiotropic Anti-Inflammatory Remedies” (PAIR) technology, delivering precision therapies that work in harmony with the body’s immune system to mitigate systemic risks associated with chronic inflammation while supporting long-term health and vitality.
Commenting on the news, Jim Iversen said: “We are thrilled to welcome 5 Horizons Capital as a financial and strategic partner to our team, on our journey to revolutionize inflammation care. Their investment and expertise in advancing clinical-stage therapies will enable us to bring SJP-001 closer to patients worldwide. With Novotech’s excellence in trial management and 5 Horizons’ visionary support, we are one step closer to transforming how the world addresses metabolic health and inflammation.”
FinSMEs
22/01/2025